Global Preventive Vaccine Market - 2023-2030
Market Overview
Preventive Vaccine Market size was valued at US$ XX million in 2023 and is estimated to reach US$ XX million by 2030, growing at a CAGR of 5.3% during the forecast period (2023-2030).
A preventive vaccine is a kind of biological preparation which stimulates immunity to a specific pathogen. A vaccine commonly contains an agent similar to the disease-causing microbe and is usually made from killed or weakened forms of the microorganism or its toxins.
Market Dynamics
The major factors driving the global preventive vaccine market are an increase in the number of diseases globally, rising research and development expenditure and awareness among the population regarding these preventive vaccines. An increase in novel product launches contributes to the growth of the preventive vaccine market.
The increasing investment in R&D and rising novel product launches are expected to drive the market’s growth.
The rising adoption of these preventive vaccine products for the prevention or treatment of various diseases, such as measles, diphtheria, polio, rubella, influenza and many more and the rising number of novel product launches drive the preventive vaccine market. An increase in diseases globally is also aiding the market growth. There has been an increase in R&D activities by many healthcare companies to develop novel products.
The preventive vaccine is used for the prevention of diseases and the spreading of these diseases in children and adults. The market for these vaccines is increasing worldwide due to the increasing number of different diseases. Moreover, the increase in research and development of novel vaccines and the availability of technologically advanced products by key players are also expected to play a vital role in the market’s growth.
Various novel product launches, regulatory approvals and research studies contribute to the market’s growth. For instance, in April 11, 2022, Mitsubishi Tanabe Pharma Corporation announced that BIKEN (The Research Foundation for Microbial Diseases of Osaka University) submitted the application to the Ministry of Health, Labour and Welfare for their jointly developed combination vaccine marketing authorization for diphtheria, prophylaxis of pertussis, tetanus, Haemophilus influenzae type b (Hib) and acute poliomyelitis (polio). According to the “National Immunization Plan,” this combination vaccine utilized for five diseases has been chosen as the vaccine with high development priority specified in 2014.
The side effects associated with preventive vaccines are expected to hamper the market’s growth.
However, various minor side effects associated with different types of vaccines may hinder the market's growth. Fever, swelling or soreness where the shot was given, fussiness, tiredness, vomiting and loss of appetite can occur after DTaP vaccination. Redness or swelling happens where the shot is given, and muscle aches, headaches and fever can happen after influenza vaccination.
After influenza vaccination, nasal congestion, runny nose, headache and wheezing can happen. In the cheeks or neck, swelling of the glands or stiffness and temporary pain in the joints (mostly in adults or teenage women) sometimes happen after MMR vaccination. Irritability, vomiting, or temporary, mild diarrhea, can occur after the rotavirus vaccine.
COVID-19 Impact Analysis
The pandemic has positively impacted global financial expectations, operations and crisis response strategy. The COVID-19 outbreak has severely impacted the healthcare industry. The preventive vaccine market has experienced huge profits due to COVID, as various research and clinical trials got started in full swing for COVID vaccine. An urgent need for vaccines to prevent the spreading of COVID and its variant across the globe. Various initiatives, product launches, innovations, collaborations and mergers are happening worldwide, boosting the market’s growth. For instance, in November 10, 2022, Sanofi and GSK announced the approval of their jointly developed VidPrevtyn Beta, the next-generation COVID-19 booster vaccine, by the European Commission for COVID-19 prevention in adults aged 18 years and older.
Segment Analysis
The live-attenuated vaccines segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)
The live-attenuated vaccines segment is the highest market holder in the global preventive vaccine market. The global preventive vaccine market is segmented based on vaccine type: live-attenuated vaccines, inactivated vaccines, subunit, recombinant, conjugate, and polysaccharide vaccines, mRNA vaccines, toxoid vaccines and viral vector vaccines. The live-attenuated vaccines segment is the largest market shareholder due to its better efficacy and results, increasing diseases and rising adoption of these preventive vaccines.
The live-attenuated vaccines utilize an attenuated or weakened form of the microbe that causes a disease. As these vaccines are like the natural infection they help avert, they provide a long-lasting and strong immune response. Most of the live vaccines, in just 1 or 2 doses, can provide a lifetime of protection contrary to the microbe and the disease caused by it. These vaccines are used for the protection against smallpox, rotavirus, yellow fever, chickenpox and combined vaccine of measles, mumps, and rubella (MMR).
The growing number of regulatory approvals, technological advancements, product launches, and research/clinical trial studies drive the market’s growth. For instance, in February 24, 2022, Mitsubishi Tanabe Pharma Corporation announced that GlaxoSmithKline plc and Medicago Inc., its affiliated company, jointly announced receiving full approval for COVIFENZ (COVID-19 vaccine) from Health Canada. COVIFENZ is a virus-like particle vaccine that is administered with the pandemic adjuvant of GSK indicated for COVID-19 prevention.
Geographical Analysis
North America holds the largest market share in the global preventive vaccine market.
North America dominates the global preventive vaccine market, primarily due to its large population, excellent medical infrastructure, and rising number of diseases. The market is expected to grow at a relatively high pace during the forecast period due to healthcare expenditure in the US. The market’s significant size is attributed to the high medical expenditure.
Increasing expenditure on healthcare and raising awareness among people is also contributing to the market’s growth in this region. Advancement of types of vaccines for prevention of different disease indications such as pneumococcal disease, varicella, human papillomavirus, influenza, meningococcal disease, MMR (measles, mumps, rubella), polio, hepatitis, dengue, DPT (diphtheria, pertussis, and tetanus), rotavirus, yellow fever, typhoid fever and more, increase in pharmaceutical establishment across the region and government approvals and the presence of key players in the region are contributing to the growth of the preventive vaccine market.
Moreover, the growing number of product launches is responsible for the market’s growth. Many key developments, regulatory approvals, technological advancements, collaborations, and agreements are taking place in this region. For instance, in October 10, 2022, GSK plc announced approval for its BOOSTRIX (Reduced Diphtheria Toxoid, Tetanus Toxoid and Acellular Pertussis Vaccine) by the US Food and Drug Administration (FDA) for immunization during the pregnancy to prevent pertussis (whooping cough) in infants.
Competitive Landscape
The preventive vaccine market is moderately competitive with local and global companies’ presence. AstraZeneca, Astellas Pharma Inc., Pfizer, Inc, Johnson & Johnson, GSK plc, Merck & Co., Inc., Sanofi, Bavarian Nordic, Emergent Biosolutions, Mitsubishi Tanabe Pharma Corporation and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market’s growth. For instance, in August 16, 2022, GSK plc announced its completion of the acquisition of Affinivax Inc, a Cambridge-based clinical-stage biopharmaceutical company. Affinivax has initiated a novel class of vaccine development. The most advanced of them are next-generation pneumococcal vaccines.
GSK PLC.
Overview: GlaxoSmith Kline is a company that develops and provides vaccines, medicines and several consumer healthcare-related products. Its products impact the health of humans on a large scale.
Product Portfolio:
VidPrevtyn Beta: It is the next-generation COVID-19 booster vaccine developed for COVID-19 prevention in adults aged 18 years and older and approved by the European Commission.
Key Developments: In February 3, 2021, GlaxoSmithKline plc and CureVac N.V. announced a novel collaboration of €150M for the joint development of next-generation mRNA vaccines for preventing COVID-19 virus with the capability for a multi-valent approach to deal with multiple emerging variants with one vaccine.
The global preventive vaccine market report would provide access to approx.: 45+ market data tables, 40+ figures and 200 (approximate) pages.
- 1. Methodology and Scope
- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report
- 2. Market Definition and Overview
- 3. Executive Summary
- 4. Market Dynamics
- 4.1. Market Impacting Factors
- 4.1.1. Drivers
- 4.1.1.1. Rise in investment in research and development
- 4.1.1.2. Surge in novel product launches
- 4.1.1.3. Increasing incidence of diseases
- 4.1.2. Restraints:
- 4.1.2.1. Side effects associated with vaccines
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis
- 5. Industry Analysis
- 5.1 Porter's Five Forces Analysis
- 5.2 Supply Chain Analysis
- 5.3 Pricing Analysis
- 6. COVID-19 Analysis
- 6.1. Analysis of Covid-19 on the Market
- 6.1.1. Before COVID-19 Market Scenario
- 6.1.2. Present COVID-19 Market Scenario
- 6.1.3. After COVID-19 or Future Scenario
- 6.2. Pricing Dynamics Amid Covid-19
- 6.3. Demand-Supply Spectrum
- 6.4. Government Initiatives Related to the Market During the Pandemic
- 6.5. Manufacturer’s Strategic Initiatives
- 6.6. Conclusion
- 7. By Vaccine Type
- 7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
- 7.1.2. Market Attractiveness Index, By Vaccine Type
- 7.2. Live-attenuated vaccines*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
- 7.3. Inactivated vaccines
- 7.4. Subunit, recombinant, conjugate, and polysaccharide vaccines
- 7.5. mRNA vaccines
- 7.6. Toxoid vaccines
- 7.7. Viral vector vaccines
- 8. By Route of Administration
- 8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 8.1.2. Market Attractiveness Index, By Route of Administration
- 8.2. Oral *
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
- 8.3. Subcutaneous
- 8.4. Other
- 9. By Disease Indication
- 9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
- 9.1.2. Market Attractiveness Index, By Disease Indication
- 9.2. Pneumococcal Disease *
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
- 9.3. Varicella
- 9.4. Human Papilloma Virus
- 9.5. Influenza
- 9.6. Meningococcal Disease
- 9.7. MMR (Measles, Mumps, Rubella)
- 9.8. Polio
- 9.9. Hepatitis
- 9.10. Dengue
- 9.11. DPT (diphtheria, pertussis, and tetanus)
- 9.12. Rotavirus
- 9.13. Yellow Fever
- 9.14. Typhoid Fever
- 9.15. Others
- 10. By End-User
- 10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 10.1.2. Market Attractiveness Index, By End-User
- 10.2. Adults *
- 10.2.1. Introduction
- 10.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
- 10.3. Pediatrics
- 11. By Region
- 11.1. Introduction
- 11.1.1. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
- 11.1.2. Market Attractiveness Index, By Region
- 11.2. North America
- 11.2.1. Introduction
- 11.2.2. Key Region-Specific Dynamics
- 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
- 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
- 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 11.2.7.1. U.S.
- 11.2.7.2. Canada
- 11.2.7.3. Mexico
- 11.3. Europe
- 11.3.1. Introduction
- 11.3.2. Key Region-Specific Dynamics
- 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
- 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
- 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 11.3.7.1. Germany
- 11.3.7.2. U.K.
- 11.3.7.3. France
- 11.3.7.4. Italy
- 11.3.7.5. Spain
- 11.3.7.6. Rest of Europe
- 11.4. South America
- 11.4.1. Introduction
- 11.4.2. Key Region-Specific Dynamics
- 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
- 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
- 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 11.4.7.1. Brazil
- 11.4.7.2. Argentina
- 11.4.7.3. Rest of South America
- 11.5. Asia Pacific
- 11.5.1. Introduction
- 11.5.2. Key Region-Specific Dynamics
- 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
- 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
- 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 11.5.7.1. China
- 11.5.7.2. India
- 11.5.7.3. Japan
- 11.5.7.4. Australia
- 11.5.7.5. Rest of Asia Pacific
- 11.6. Middle East and Africa
- 11.6.1. Introduction
- 11.6.2. Key Region-Specific Dynamics
- 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
- 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
- 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 12. Competitive Landscape
- 12.1. Key Developments and Strategies
- 12.2. Company Share Analysis
- 12.3. Products Benchmarking
- 12.4. List of Key Companies to Watch
- 13. Company Profiles
- 13.1. AstraZeneca *
- 13.1.1. Company Overview
- 13.1.2. Product Portfolio and Description
- 13.1.3. Key Highlights
- 13.1.4. Financial Overview
- 13.2. Astellas Pharma, Inc.
- 13.3. Pfizer, Inc
- 13.4. Johnson & Johnson
- 13.5. GSK plc
- 13.6. Merck & Co., Inc.
- 13.7. Sanofi
- 13.8. Bavarian Nordic
- 13.9. Emergent Biosolutions
- 13.10. Mitsubishi Tanabe Pharma Corporation
- LIST NOT EXHAUSTIVE
- 14. Global Preventive Vaccine Market – DataM
- 14.1. Appendix
- 14.2. About Us and End-User
- 14.3. Contact Us
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook